Newsroom

Title
MegaPro Biomedical MPB1523 Nano-MRI contrast agent makes a breakthrough and works with Stanford University in the CAR-T cell therapy experiment, which was published at the WMIC conference
MegaPro Medical’s new MRI contrast agent MPB-2043 has completed the first patient admission in Taiwan
MegaPro (6827)’s new drug MPB-2354 issues a press release on WMIS
MegaPro (6827) MPB-1734 completes the phase 1 of the last patient, press release
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
Expanding the application field again, MegaPro Biomedical IOP enters the field of cell therapy
MegaPro Biomedical (6827) MPB-1523 Published in Authoritative Medical Journals
MegaPro, CCPC, and Wellbridge Jointly Establishes an Inhalation Dosage Form Company
MegaPro Biomedical (6827) Successfully Completed IOP Vaccine Adjuvant Cell Experiment Press Release
First Clinical Case Completion of the MPB1734